The company, established in late 2019, aims to contribute to the demand in Arab countries for essential, commonly used vaccines, such as those for livestock foot-and mouth disease, bird flu and Newcastle disease, among others.
Free Zone Port of Sohar-Sultanate of Oman
Ghala, Bousher, Muscat Governorate
ali.alsahmy@nvvco.com
P.O. Box61, Zip code: 134
The maximum production capacity is 2.7 billion doses (tenth years)
The Initial capital is OMR 200 thousand, and shareholders are:
AAAID
Oman Food Investment Holding Company (SAOC)
The company's sales at stability year (the tenth year of production) are estimated at USD 78.7 million
The market share is estimated at 1% in 2026-2027 and graded to 10% in 2028-2029 and 20% in 2035.
- Foot Mouth Disease (FMD) vaccine
- Newcastle vaccine, bird flu vaccine, and others.
The total investment cost of the project is USD 104 million, representing investment cost of USD 52.1 Million at phase I and USD 51.9 million at phase II.
The two phases will be financed by 58% loans and 42% Equity.
Participation in equity and/or Provision of loans to complete implementation of project components.
